Key facts
- This page summarizes Eric Venker's Form 4 filing for Roivant Sciences Ltd. (ROIV).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Sep 2023, 21:30.
Eric Venker - 22 Sep 2023 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)
- Reporting relationship
- President & COO
- Issuer ticker
- ROIV
- Reported as of
- 22 Sep 2023
- Net transaction value
- -$167,279
- SEC form
- 4
- Accepted by SEC
- 26 Sep 2023, 21:30:49 UTC
- Prior SEC filing
- 12 Sep 2023
- Next SEC filing
- 29 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Venker filed Form 4 for Roivant Sciences Ltd. (ROIV) on 26 Sep 2023.
Change
- Previous filing in this sequence was filed on 12 Sep 2023.
- Current net transaction value: -$167,279.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ROIV
transaction
Common Shares
Other
- Transaction value
- $167,279
- Shares
- -16,416
- Change %
- -2.7%
- Price
- $10.19
- Shares after
- 595,397
- Date
- 22 Sep 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.
Footnote F2
The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.